Alterity Therapeutics (ATHE) Share-based Compensation (2009 - 2020)

Alterity Therapeutics' Share-based Compensation history runs 10 years deep, the most recent figure standing at -$7875.5 for Q2 2020.

• On a quarterly basis, Share-based Compensation fell 112.61% year-over-year to -$7875.5 in Q2 2020; TTM through Jun 2020 was $3611.4, a 103.18% increase from a year earlier, with the FY2025 full-year figure at $627573.3, up 7.97% from the prior year.
• Share-based Compensation slipped to -$7875.5 in Q2 2020 per ATHE's latest filing, from $62438.7 in the prior quarter.
• Across five years, Share-based Compensation topped out at $62438.7 in Q2 2019 and bottomed at -$124886.5 in Q4 2017.
• The 4-year median for Share-based Compensation is -$1043.8 (2020), against an average of -$17150.1.
• Across the five-year window, Share-based Compensation soared 978.79% in 2019 and tumbled 112.61% in 2020, its largest moves.
• Year by year, Share-based Compensation stood at -$124886.5 in 2017, then surged by 54.57% to -$56739.6 in 2018, then jumped by 210.04% to $62438.7 in 2019, then plunged by 112.61% to -$7875.5 in 2020.
• Per Business Quant, the three latest ATHE Share-based Compensation figures stand at -$7875.5 (Q2 2020), $62438.7 (Q2 2019), and -$56739.6 (Q4 2018).